Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: IDYA stock price vs AXP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AXP's multiple
Needs AXP P/B.
Implied fair value · at IDYA's multiple
Needs IDYA P/B.
Metric by metric
Price unavailable
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · AXP FY 2025 (ended Dec 31, 2025).
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity
—
Price / tangible book
—
Price / book
—
Return on equity
-11.1%
Return on assets
-10.2%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity
$28.51B
Price / tangible book
—
Price / book
—
Return on equity
32.4%
Return on assets
3.6%
Efficiency ratio
72.2%
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
IDEAYA Biosciences, Inc. · implied price per share
Bear
$0.30
Base
$0.35
Bull
$0.41
AMERICAN EXPRESS CO · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.07x
1.73x
Net debt / EBITDA
Leverage against operating earnings
5.09x
1.97x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$1.40B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
Visa Inc.
IDYA vs V
Mastercard Incorporated
IDYA vs MA
CAPITAL ONE FINANCIAL CORP
IDYA vs COF
PayPal Holdings, Inc.
IDYA vs PYPL
Synchrony Financial
IDYA vs SYF
$70.35M
$57.76B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Live quote
